INmune Bio and CGT Catapult: A Strategic Partnership for Large-Scale Commercial Manufacturing of Cell Therapy Platforms
April 14, 2025 – INmune Bio Inc. (INMB), a clinical-stage biotechnology company based in the United States, focusing on inflammation and immunology through the innate immune system, has announced a new partnership with the Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. This collaboration aims to establish large-scale, commercial-ready manufacturing for INmune Bio’s cell therapy platforms.
About INmune Bio
INmune Bio is a trailblazing biotech company dedicated to targeting inflammation and immunology through the innate immune system. The company’s innovative approach focuses on developing therapies for various diseases, including cancer, neurological disorders, and infectious diseases. With its commitment to groundbreaking research and development, INmune Bio continues to push the boundaries of science to bring life-changing treatments to patients.
About CGT Catapult
CGT Catapult is a leading organization that plays a pivotal role in the cell and gene therapy industry. Established by Innovate UK, CGT Catapult’s mission is to advance the sector by providing state-of-the-art facilities, expertise, and resources to support companies in the development, manufacturing, and commercialization of their therapies. By fostering collaborations and driving innovation, CGT Catapult is instrumental in transforming scientific discoveries into clinical realities.
The Strategic Partnership
The partnership between INmune Bio and CGT Catapult represents a significant milestone for both organizations. INmune Bio will leverage CGT Catapult’s advanced manufacturing capabilities to scale up its cell therapy platforms for commercial production. This collaboration is expected to accelerate INmune Bio’s development timeline and bring its promising therapies to market more efficiently.
Impact on the Individual
For individuals, this partnership could potentially lead to faster access to innovative cell therapies. By enabling INmune Bio to manufacture its therapies at a larger scale, more patients may have access to these life-changing treatments. Additionally, the partnership may result in lower costs due to increased economies of scale, making these therapies more affordable for a broader population.
Impact on the World
On a global scale, this partnership signifies a major step forward in the cell and gene therapy industry. By fostering collaborations between innovative biotech companies and advanced manufacturing organizations, we can expect to see more groundbreaking therapies reach the market more quickly and efficiently. This, in turn, could lead to improved health outcomes for patients worldwide and contribute to the overall advancement of healthcare.
Conclusion
The partnership between INmune Bio and CGT Catapult marks an exciting development in the cell and gene therapy industry. By combining INmune Bio’s pioneering research and development efforts with CGT Catapult’s advanced manufacturing capabilities, they aim to bring life-changing therapies to patients more efficiently. This collaboration not only stands to benefit individuals by providing faster access to innovative treatments but also contributes to the global advancement of healthcare by accelerating the development and commercialization of groundbreaking therapies.
- INmune Bio and CGT Catapult partner for large-scale commercial manufacturing of cell therapy platforms
- INmune Bio is a clinical-stage biotech company focused on inflammation and immunology through the innate immune system
- CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry
- Partnership aims to accelerate INmune Bio’s development timeline and bring therapies to market more efficiently
- Individuals may benefit from faster access to innovative treatments and potentially lower costs
- Global impact includes improved health outcomes and accelerated development of groundbreaking therapies
